Anaptysbio (ANAB) Profit After Tax (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Profit After Tax data on file, last reported at -$53.0 million in Q1 2026.

• Quarterly Profit After Tax fell 34.28% year-over-year to -$53.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.9 million (up 80.72% YoY) and the FY2025 annual result came in at -$13.2 million, up 90.89% from the prior year.
• Profit After Tax slipped to -$53.0 million in Q1 2026, from $49.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $49.6 million in Q4 2025 to a low of -$53.0 million in Q1 2026.
• A 5-year average of -$29.4 million and a median of -$37.3 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 7488.34% — and 2025, when it jumped 327.75%.
• Tracing ANAB's Profit After Tax over 5 years: stood at -$20.8 million in 2022, then slumped by 102.66% to -$42.2 million in 2023, then soared by 48.39% to -$21.8 million in 2024, then jumped by 327.75% to $49.6 million in 2025, then slumped by 206.84% to -$53.0 million in 2026.
• The last three Profit After Tax figures came in at -$53.0 million (Q1 2026), $49.6 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.